Science & technology · Pipeline & development
Actinium-225 Pretargeted Radioimmunotherapy against Colorectal Cancer using Self-Assembling and Disassembling Antibodies
Colorectal cancer (CRC) remains a leading cause of cancer deaths worldwide. GPA33, expressed on 95% of CRC, has been extensively targeted by IgG-attached payloads in conventional radioimmunotherapy (RIT), but toxicity was dose-limiting. A 2-step pretargeted radioimmunotherapy (PRIT) regimen using Self-Assembling-Disassembling antibody (SADA) specific for GPA33 (10 mg/kg) intravenous (IV) in step #
Original source
Read the source — biorxiv.org ↗We link to the original publisher. The summary above is a short guide; read the original for the full details.